Ключевые вопросы антибактериальной терапии обострений хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2011-0-4-87-96

Полный текст:


Об авторе

Л. И. Дворецкий
Первый Московский государственный медицинский университет им. И.М.Сеченова
Россия

д. м. н., проф., зав. кафедрой госпитальной терапии № 2 лечебного факультета 

119991, Москва, ул. Трубецкая, 8. Тел.: (499) 248-53-05.



Список литературы

1. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.

2. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

3. Elmes P.C., King T.K., Langlands J.H. et al. Value of ampcillin in the hospital treatment of exacerbations of chronic bronchitis. Br. Med. J. 1965; 2: 904–908.

4. Jorgensen A.F., Coolidge J., Pedersen P.A. et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: a double-blind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Hlth Care 1992; 10: 7–11.

5. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 2001; 358: 2020–2025.

6. Pines A., Raafat H., Plucinski K. et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. Br. Med. J. 1968; 2: 735–738.

7. Allegra L.,Grassi C., Grossi E., Pozzi E. Ruolo degli antidiotici nel trattamento delle riacutizza della bronchite cronica. Ital. J. Chest Dis. 1991; 45: 138–148.

8. Saint S., Bent S., Vittinghof E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J.A.M.A. 1995; 273; 957–960.

9. Ram F., Rodriguez)Roisin R., Granados)Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3.

10. Puhan M., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.

11. Blasi F., Ewig S., Torres A., Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm. Pharmacol. Ther. 2006; 19: 361–369.

12. Beghi G., Berni F., Carratu L. et al. Efficacy and tolerability of azithromycin versus amoxicillin / clavulanic acid in acute purulent exacerbation of chronic bronchiis. J. Chemother 1995; 7: 146–152.

13. Anzueto A., Fisher C.L.Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.

14. Martinot J.B., Carr W.D., Cullen S. et al. A comparative study of clarithromycin modified release and amoxicillin / clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv. Ther. 2001; 18: 1–11.

15. Hoepelman I.M., Mollers M.J., van Schie M.H. et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents 1997; 9: 141–146.

16. Martinez F.J., Grossman R.F., Zadeikis N. et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J. 2005; 25: 1001–1010.

17. Starakis I., Gogos C.A., Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 2004; 23: 129–137.

18. Schaberg T., Ballin I., Huchon G. et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res. 2001; 29: 314–328.

19. File T., Schlemmer B., Garau J. et al. Gemifloxacin versus amoxicillin / clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study Group. J. Chemother. 2000; 12: 314–325.

20. Siempos I., Dimopoulos G., Korbila I. et al. Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127–1137.

21. Dooley K.E., Golub J., Goes F.S. et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin. Infect. Dis. 2002; 34: 1607–1612.

22. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

23. Chang K.C., Leung C.C. Meta-analysis may not be practicable for guiding antibiotic therapy. Eur. Respir. J. 2008; 31: 906–907.

24. WHO model prescribing information. Drugs used in bacterial infections. Geneva: WHO; 2001.

25. Neu H.C., Wilson A.P., GrunebergR.N. Amoxycillin / clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J. Chemother. 1993; 5: 67–93.

26. Garau J., Twynholm M., Garcia)Mendez E. et al. Oral pharmacokinetically enhanced co-amoxiclav 2000 / 125 mg, twice daily, compared with co-amoxiclav 875 / 125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 2003; 52: 826–836.

27. Henry D.C., Riffer E., Sokol W.N. et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob. Agents Chemother. 2003; 47: 2770–2774.

28. File T.M.Jr., Lode H., Kurz H. et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000 / 125 milligrams) versus those of amoxicillin-clavulanate (875 / 125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2004; 48: 3323–3331.

29. Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator filmcoated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.

30. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80.

31. Wilkinson T.M., Donaldson A., Gavin C. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004, 169:1298–1303.

32. Rothberg M.B., Pekow P.S., Lahti M. et al. Аntibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. J.A.M.A. 2010; 303 (20): 2035–2042.

33. Falagas M.E., Avgeri S.G., Matthaiou D.K. et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 2008; 62 (3): 442–450.

34. El Moussaoui R., Roede B.M., Speelman P. et al. Shortcourse antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63 (5): 415–422.

35. Roede B.M., Bresser P., El Moussaouri R. et al. Three vs 10 days of amoxicillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomized, double-blind study. Clin. Microbiol. Infect. 2007; 13: 284–290.

36. Pechere J.C. Modeling and predicting clinical оutcomes of antibiotic therapy. Infect. Med. 1998; 15 (Suppl. E): 46–50.

37. Wilson R., Allegra L., Huchon G. et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur. Respir. J. 2003; 22 (Suppl. 45): 3559A.

38. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. арх. 2006; 3:25–35.

39. Anzueto A., Rizzo J., Grossman R. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin. Infect. Dis. 1999; 28: 1344–1345.

40. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–2236.

41. White A.J., Gompertz S., Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.

42. Miravitlles M. Grupo de trabajo de la Asociacion Latinoamericana del Torax (ALAT). Update to the Latin American Thoracic Association (ALAT) recommendations on infectious exacerbation of chronic obstructive pulmonary disease. Arch. Bronconeumol. 2004; 40: 315–325.

43. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Инфекционное обострение хронической обструктивной болезни легких. (Практические рекомендации по диагностике, лечению и профилактике). Рос. мед. вестн. 2006; 12: 4–18.

44. Albertson Т.E., Chan A.L. Antibiotic Therapy in elderly patients with acute exacerbation of chronic bronchitis. Exp. Rev. Respir. Med. 2009; 3 (5): 539–548.

45. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.

46. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. и антимикроб. химиотер. 2006; 8 (1): 33–47.

47. Филимонова О.Ю., Грудинина С.А., Сидоренко С.В. и др. Антибиотикорезистентность штаммов Haemophilus influenzae, выделенных в Москве с 2002 по 2004 гг. Антибиотики и химиотер. 2004; 49 (12): 14–20.

48. Jacobs M.R., Felmingham D., Appelbaum P.C. et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.

49. Авдеев С.Н., Шанина А.Г., Чучалин А.Г. Бактериальная инфекция у больных ХОБЛ с острой дыхательной недостаточностью. Клин. микробиол. и антимикроб. химиотер. 2005; 7 (3): 245–254.

50. Esel D., Ay)Altintop Y., Yagmur G. et al. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis. Clin. Microbiol. Infect. 2007; 13: 1023–1025.

51. Beekmann S.E., Heilmann K.P., Richter S.S. et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP Surveillance Program. Int. J. Antimicrob. Agents 2005; 25: 148–156.

52. Pankuch G.A., Jueneman S.A., Davies T.A. et al. In vitro selection of resistance to four beta-lactams and azithromycin in S. pneumoniae. Antimicrob. Agents Chemother. 1998; 42: 2914–2918.

53. Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002, 347, 465–471.

54. Bont J., Hak E., Birkhoff C.E. et al. Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations? Fam. Pract. 2007; 24 (4): 317–322.

55. Pechere J., Hughes D., Kardas P., Cornaglia G. Non compliance with antibiotic therapy for acute community infections: a global survey. Int. J. Antimicrob. Agents 2007; 29: 245–253.

56. Kardas P. Comparison of patient compliance with oncedaily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J. Аntimicrob. Сhemother. 2007; 59 (3): 531–536.

57. Niederman M.S. What are the benefits of antibiotics in acute exacerbations of COPD? In: 13th ERS annual congress, Vienna; 2003.

58. Wistrom J., Norrby S.R., Myhre E.B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 2001: 47 (1): 43–50.


Дополнительные файлы

Для цитирования: Дворецкий Л.И. Ключевые вопросы антибактериальной терапии обострений хронической обструктивной болезни легких.  Пульмонология. 2011;(4):87-96. https://doi.org/10.18093/0869-0189-2011-0-4-87-96

For citation: Dvoretsky L.I. Key points of antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease. Russian Pulmonology. 2011;(4):87-96. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-4-87-96

Просмотров: 250

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)